None

Prospectively reported data from more than 150 pregnancies in patients treated with teriflunomide (Teriflunomide) and more than 300 pregnancies in patients treated with leflunomide have not shown an increased incidence of congenital malformations or miscarriages after exposure to teriflunomide in early pregnancy and subsequent accelerated elimination procedures.

Based on animal data, teriflunomide is contraindicated in pregnant women and females of childbearing potential who are not using effective contraception due to potential harm to the fetus, and accidental exposure to teriflunomide in early pregnancy has been associated with increased birth defects or miscarriage after accelerated elimination procedures. There are no data on the presence of teriflunomide in human milk, the effects on the breastfed infant, or the effects on milk production. Teriflunomide has been detected in rat milk following a single oral dose. Because of the potential adverse effects of teriflunomide in breastfed infants, women should not breastfeed during teriflunomide treatment.

The original drug Teriflunomide has been marketed in China and has entered the scope of medical insurance through medical insurance reimbursement standards. It may be limited to patients with multiple sclerosis who are ineffective in conventional treatments. However, the reimbursement ratio is different in different regions, and the price after reimbursement is different. SpecificationsThe price of 14mg*28 tablets per box is about 10,000 yuan. For families with heavy financial burdens, the high price may increase their pressure. Cheaper generic drugs are also sold in other overseas countries. The pharmaceutical ingredients of generic drugs are basically the same as those of the original drugs. The price of 14mg*30 tablets produced by an Indian pharmaceutical factory is around RMB 800 per box (the price may fluctuate due to the exchange rate).